Get the Stockscreener App
0.5799
1.40%
0.008
After Hours:
.57
-0.0099
-1.71%
Plus Therapeutics Inc stock is traded at $0.5799, with a volume of 1.93M.
It is up +1.40% in the last 24 hours and down -3.08% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.5719
Open:
$0.574
24h Volume:
1.93M
Relative Volume:
0.11
Market Cap:
$79.70M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2292
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+2.01%
1M Performance:
-3.08%
6M Performance:
+58.18%
1Y Performance:
-46.31%
1-Day Range:
$0.556
$0.5799
1-Week Range:
$0.5376
$0.60
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.5799 | 78.60M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
How Plus Therapeutics Inc. stock reacts to job market dataRetail Investor Activity & Master Technical Analysis With Free Tools - bollywoodhelpline.com
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Death Cross: How Plus Therapeutics Inc. stock reacts to job market data2025 Price Targets & Low Volatility Stock Recommendations - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Inflation Data: Can Plus Therapeutics Inc. stock continue upward trendTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Can Plus Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics (Nasdaq: PSTV) CNSide test now licensed in 48 states, reaching over 90% of U.S. - Stock Titan
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Plus Therapeutics granted 180-day to regain compliance with Nasdaq - MSN
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
HC Wainwright Expects Weaker Earnings for Plus Therapeutics - MarketBeat
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 By Investing.com - Investing.com South Africa
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):